Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
about
Hepatocellular carcinoma in elderly patients: challenges and solutionsFrequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systemsEfficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaA Pilot Study to Determine the Effect of an Educational DVD in Philippine Languages on Cancer Clinical Trial Participation among Filipinos in Hawai'i.Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry.The impact of age on outcome in early-stage breast cancerManagement of elderly patients with gliomasParticipation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experienceSurvival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.Systemic therapy for elderly patients with gastrointestinal cancer.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer.Chemotherapy-related hospitalization among community cancer center patientsOutcomes of resected pancreatic cancer in patients age ≥70.Effects of baseline comorbidities on cancer screening trial adherence among older African American menChemotherapy for older patients with prostate cancer.Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysisPrognostic impact of breast cancer subtypes in elderly patients.Treatment of breast cancer in older women.Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.Colorectal cancer patients' attitudes towards involvement in decision making.Treatment outcomes in elderly with advanced-stage non-small cell lung cancerDo we protect or discriminate? Representation of senior adults in clinical trials.Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit.Assessment of cancer care in Indian elderly cancer patients: A single center study.Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeRecommendations for enhancing clinical trials education: a review of the literature.A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.Comparison of self-expanding metal stents and urgent surgery for left-sided malignant colonic obstruction in elderly patients.Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients.Systemic treatment of gastrointestinal cancer in elderly patients.Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review.Participation of the elderly population in clinical trials: barriers and solutions.Treating glioblastoma in the elderly.Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.
P2860
Q26738274-BB997DCF-054C-4750-9EE8-9C4AF65897FCQ33372268-88F33CB4-C5E8-4050-A276-4BF3ED0E45C2Q33387054-E3DC1C62-CD71-49E6-A9EE-DA8394E281E3Q33412728-8F1A9B1E-738E-4513-BC06-F9DCD57737A3Q33906330-3FAB963A-43C8-4D09-B631-03E9F3146FEAQ34221473-CA4AF100-9548-481F-95AF-A6C2A6625280Q34359352-83F52C2A-3B7F-428B-A6F4-DFDCE5772CEBQ34584831-1E10ED43-A046-4B53-8ABF-EBD1763F4A12Q34641001-6B101FB8-6129-482D-90AD-6F6428EE7549Q34801461-1E8468B5-130C-4100-B7AF-97E5741B60FAQ34890475-24B3A33A-9841-471B-9754-2775CF423BC6Q34982764-B16B0718-7705-43C3-B599-6DD910F309A8Q35236068-FA04DBE2-4A63-4C75-BC8D-0A7B00FC7366Q35583728-DAB588BD-3FF5-42EE-BD33-F86C73C12C48Q35584511-A0C3ACFD-64D0-4647-8204-7C24C0C47A8EQ36062611-63B0C4DC-B3C0-488E-96C4-7F2BF008DFA5Q36180472-C8D644BE-CCED-4496-844A-BD6388ABDE28Q36596741-3DF0C58F-8625-4F30-8239-B42FE8808DE8Q36609867-181C55E2-5712-42D9-8041-D8F0E18699E3Q36901185-92C7F422-25F5-41E7-AC6C-BFE097090F23Q36953425-F08C3916-9720-40A7-BDE5-DC5C09CC6D47Q37283736-EC694EA0-CA21-4306-ACBD-54BDF9947395Q37298994-A89014B1-3CE4-4307-AAD4-EDE488A5D0B2Q37332405-74580328-19ED-47A0-B9D2-1C0F9BD7387DQ37333926-3062DE93-93E9-4E58-9A52-6CDF65FA13C6Q37392261-F09BAB84-45A0-40C7-8492-C5D91A8DA1D5Q37404400-342548FF-08C8-479C-A6A5-BB236470E568Q37467168-50327D47-95BF-4FD7-9AAC-E77399E41667Q37596123-8183B1D0-398A-480C-AECB-865EFD001F70Q37626917-87AC9BC3-D78E-4143-A0F6-285847B298C3Q37718203-88A70CCA-A972-421C-AB67-1BC154DD0BCAQ37791483-D64D6CB8-E773-481D-BFB8-03BA106BD98FQ37809571-2423F029-9A05-4BC9-98C8-07FA9C94B4CFQ37858453-B3C9B2DB-C302-4EE6-AB8A-7C26521E48CCQ37954162-881215F1-A9A6-4704-BD2E-F6872881E4AFQ38059634-66F3683B-6DA3-4DDA-95F3-B174A43FA7D4Q38191160-26E0445F-F7EA-42D7-940A-87C2C31BB2EDQ38222467-D3300659-573C-43E8-AAA5-F6A128B0F20AQ38233427-ACF91180-91EF-41A2-9A1D-7449F2A69745Q38961110-114E61B0-C56B-4D36-85B6-AF35E57DF65F
P2860
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@ast
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@en
type
label
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@ast
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@en
prefLabel
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@ast
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@en
P2093
P1433
P1476
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
@en
P2093
Harvey Jay Cohen
Martine Extermann
Matti S Aapro
P304
P356
10.1634/THEONCOLOGIST.10-3-198
P577
2005-03-01T00:00:00Z